Pentosan Polysulfate Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Pentosan Polysulfate evidence and protocol review

Structural Research compound CapsuleInjection research formulationPowder needs_revision Best effort · source review pending

Also known as: PPS

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

1 g, 5 g

Storage

No approved consumer storage standard exists for this presentation; follow the lot-specific COA and validated stability data

Solubility

Water-soluble sodium salt; injectable form available

Best-Effort Research Profile

Pentosan polysulfate sodium is a semi-synthetic sulfated polysaccharide, FDA-approved as Elmiron for interstitial cystitis/bladder pain syndrome, thought to help restore the protective glycosaminoglycan layer of the bladder wall. Separately, research on related sulfated polysaccharides (SAGEs) shows they bind LL-37 (cathelicidin) and inhibit LL-37-induced interleukin-8 production in keratinocytes, preventing cathelicidin-driven skin inflammation in animal models - a mechanism of research interest for inflammatory skin conditions.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Variable; primarily acts locally within the urinary tract at approved doses

Onset

Interstitial cystitis symptom improvement typically assessed over months per approved-use trials

Administration Routes (Research)

Oral

Reported Research Effects

Approved use: restores bladder glycosaminoglycan layer (interstitial cystitis)
Binds and neutralizes LL-37/cathelicidin activity in preclinical skin-inflammation research

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

100 mg three times daily [Oral; Reassess after 3 months; Three times daily]Source: ELMIRON prescribing information

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Active bleeding
Anticoagulants or antiplatelets without prescriber review

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

The FDA-approved U.S. product is oral ELMIRON for interstitial cystitis. Experimental SC osteoarthritis regimens are not interchangeable; long-term pigmentary maculopathy risk requires explicit labeling.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources Under Review

ELMIRON pentosan polysulfate sodium prescribing information — DailyMed (NIH)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7417e03-5812-4f35-8433-6062d68420fc

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.